Literature DB >> 12958210

Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.

Michel Cyr1, Jean-Martin Beaulieu, Aki Laakso, Tatyana D Sotnikova, Wei-Dong Yao, Laura M Bohn, Raul R Gainetdinov, Marc G Caron.   

Abstract

Dopamine is believed to contribute to the degeneration of dopamine-containing neurons in the brain. However, whether dopamine affects the survival of other neuronal populations has remained unclear. Here we document that mice with persistently elevated extracellular dopamine, resulting from inactivation of the dopamine transporter gene, sporadically develop severe symptoms of dyskinesia concomitant with apoptotic death of striatal dopamine-responsive gamma-aminobutyric acidergic neurons. Chronic inhibition of dopamine synthesis prevents the appearance of motor dysfunction. The neuronal death is associated with overactivation of dopaminergic signaling as evidenced by the robust up-regulation of striatal DeltaFosB, cyclin-dependent kinase 5, and p35. Moreover, hyperphosphorylation of the tau protein, a phenomenon associated with the activation of cyclin-dependent kinase 5 in several neurodegenerative disorders, is observed in symptomatic mice. These findings provide in vivo evidence that, in addition to its proposed role in the degeneration of dopamine neurons, dopamine can also contribute to the selective death of its target neurons via a previously unappreciated mechanism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958210      PMCID: PMC196922          DOI: 10.1073/pnas.1831768100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease.

Authors:  P K Tekumalla; F Calon; Z Rahman; S Birdi; A H Rajput; O Hornykiewicz; T Di Paolo; P J Bédard; E J Nestler
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

3.  DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization.

Authors:  C C Ouimet; P E Miller; H C Hemmings; S I Walaas; P Greengard
Journal:  J Neurosci       Date:  1984-01       Impact factor: 6.167

4.  Loss of striatal neurons in Parkinson's disease: a cytometric study.

Authors:  O Bugiani; F Perdelli; S Salvarani; A Leonardi; G L Mancardi
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

5.  Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Authors:  Kristin E Larsen; Edward A Fon; Teresa G Hastings; Robert H Edwards; David Sulzer
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

6.  Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease.

Authors:  Thomas Fath; Jochen Eidenmüller; Roland Brandt
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

7.  Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy.

Authors:  R Borghi; L Giliberto; A Assini; A Delacourte; G Perry; M A Smith; P Strocchi; D Zaccheo; M Tabaton
Journal:  Neurology       Date:  2002-02-26       Impact factor: 9.910

8.  Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions.

Authors:  M D Nguyen; R C Larivière; J P Julien
Journal:  Neuron       Date:  2001-04       Impact factor: 17.173

9.  D1 dopamine receptor regulation of microtubule-associated protein-2 phosphorylation in developing cerebral cortical neurons.

Authors:  Z-M Song; A S Undie; P O Koh; Y-Y Fang; L Zhang; S Dracheva; S C Sealfon; M S Lidow
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

Review 10.  Monoamine transporters: from genes to behavior.

Authors:  Raul R Gainetdinov; Marc G Caron
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-09-17       Impact factor: 13.820

View more
  57 in total

Review 1.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

3.  A dopamine receptor contributes to paraquat-induced neurotoxicity in Drosophila.

Authors:  Marlène Cassar; Abdul-Raouf Issa; Thomas Riemensperger; Céline Petitgas; Thomas Rival; Hélène Coulom; Magali Iché-Torres; Kyung-An Han; Serge Birman
Journal:  Hum Mol Genet       Date:  2014-08-25       Impact factor: 6.150

4.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

5.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

6.  Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells.

Authors:  Francisco J Diaz-Corrales; Masato Asanuma; Ikuko Miyazaki; Ko Miyoshi; Nobutaka Hattori; Norio Ogawa
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

7.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

8.  Tetrabenazine is neuroprotective in Huntington's disease mice.

Authors:  Hongyu Wang; Xi Chen; Yuemei Li; Tie-Shan Tang; Ilya Bezprozvanny
Journal:  Mol Neurodegener       Date:  2010-04-26       Impact factor: 14.195

9.  Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells.

Authors:  Masoome Khalife; Dina Morshedi; Farhang Aliakbari; Amir Tayaranian Marvian; Hossein Mohammad Beigi; Sadegh Azimzadeh Jamalkandi; Francisco Pan-Montojo
Journal:  Protein J       Date:  2015-08       Impact factor: 2.371

10.  Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation.

Authors:  Carole Deyts; Beatriz Galan-Rodriguez; Elodie Martin; Nicolas Bouveyron; Emmanuel Roze; Delphine Charvin; Jocelyne Caboche; Sandrine Bétuing
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.